Orchard Therapeutics plc (ORTX) News

Orchard Therapeutics plc (ORTX): $0.48

-0.01 (-2.69%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ORTX News Items

ORTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ORTX News From Around the Web

Below are the latest news stories about Orchard Therapeutics plc that investors may wish to consider to help them evaluate ORTX as an investment opportunity.

Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles

Orchard Therapeutics (ORTX), which I covered in multiple articles over the past year, is a leading gene therapy developer. In 2018, ORTX stuck a deal whereby, against a 20% stake and a position on its BoD, GlaxoSmithKline (GSK) sold it their entire gene therapy program. Orchard's non-GSK asset Strimvelis is...

Avisol Capital Partners on Seeking Alpha | NA NA, NA


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4883 seconds.